We are live on ! Find out more
PVCT

Provectus Biopharmaceuticals
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

3 hedge funds and large institutions have $11K invested in Provectus Biopharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% less funds holding

Funds holding: 4 → 3 (-1)

50% less capital inflows, than outflows

Capital inflows: $1K | Capital outflows: $2K

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Quad-Cities Investment Group
Quad-Cities Investment Group
Iowa
+$1K

PVCT Hedge Fund Activity: Q2 2018 in Review

3 of the 4,387 institutional investors tracked by Wall St. Rank reported a position in Provectus Biopharmaceuticals (PVCT) for Q2 2018, worth a combined $11K — up 10% from $10K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of PVCT and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was Quad-Cities Investment Group, opening a new position worth an estimated $1K. The largest seller was Academy Capital Management, exiting entirely with an estimated $1K sold.

  • 3 institutional investors held Provectus Biopharmaceuticals (PVCT) as of Q2 2018, down from 4 in Q1 2018.
  • Funds reported $11K of Provectus Biopharmaceuticals stock for Q2 2018, up 10% quarter-over-quarter.
  • 1 fund opened new Provectus Biopharmaceuticals positions in Q2 2018 and 2 closed out, a net change of -1 holder.
  • The largest Provectus Biopharmaceuticals buyer in Q2 2018 was Quad-Cities Investment Group, an estimated $1K added.
  • The largest Provectus Biopharmaceuticals seller in Q2 2018 was Academy Capital Management, an estimated $1K sold.

Based on aggregated 13F filings for Q2 2018.